Tvardi Therapeutics, Inc. (TVRD) 股票分析

公司概述

Tvardi Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company dedicated to the development of novel, oral, and small molecule therapies specifically targeting signal transducer and activator of transcription 3 (STAT3) for the treatment of inflammatory and proliferative diseases. The company functions within the Healthcare sector, specifically under the Biotechnology industry, positioning itself to address significant unmet medical needs in these therapeutic areas. As of the latest data, the entity maintains a market capitalization of $28.61M and employs a workforce of 12 individuals. The combination of a sub-$30 million market cap and a reported revenue of N/A indicates that the company is in an early-stage development phase where financial resources are primarily allocated to research and development rather than commercial revenue generation, reflecting the typical profile of a clinical-stage biotech firm prior to widespread market entry.

财务健康

The company reports a net income of $-18,214,000 for the trailing twelve months, while its revenue is listed as N/A, and its EBITDA stands at $-26,653,000. The substantial gap between the reported revenue (N/A) and the negative net income reveals a cost structure heavily weighted towards operational expenses and R&D costs rather than commercial profitability, which is characteristic of companies in the clinical development stage. Free cash flow is recorded at $-15,216,500, indicating that the company is burning cash to fund its operations and drug development pipeline, which limits immediate financial flexibility but is a necessary expenditure for clinical-stage entities. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are reported at 0.0%, suggesting that either no revenue has been recognized commercially yet or that costs have fully consumed any generated revenue, resulting in a lack of traditional profit margins. On the balance sheet, the company holds $30.81M in cash against $201,000 in debt, supported by a debt-to-equity ratio of 0.96. While the debt-to-equity ratio of 0.96 suggests a moderate level of leverage, the overwhelming presence of cash relative to the minimal debt indicates a relatively conservative liquidity position regarding solvency. The current ratio is 2.86, which signifies that the company possesses 2.86 dollars of current assets for every one dollar of current liabilities, pointing to robust short-term liquidity and the ability to meet its financial obligations without immediate distress. Return on Equity is -237.8% and Return on Assets is -49.7%, metrics that reveal that management has not yet generated positive returns on the capital invested or the assets held, a common feature in early-stage biotechnology where capital is deployed to create future value rather than immediate earnings.

估值评估

The P/E Ratio (TTM) is N/A due to the lack of positive earnings, while the Forward P/E is listed as -1.17, a metric that implies the market is pricing in significant expected earnings growth or a turnaround that has not yet materialized in trailing figures. The Price to Book ratio is 1.37, indicating that the market values the company at a premium of 37% over its net asset book value, which often reflects intangible assets like intellectual property and clinical pipeline potential that are not fully captured on the balance sheet. Alternative valuation metrics such as Price to Sales (N/A) and EV/EBITDA (0.07) provide further context; the low EV/EBITDA of 0.07 suggests the company's enterprise value is closely tied to its cash position given the negative earnings, while the absent price-to-sales figure reinforces the absence of commercial sales data for valuation comparison. The stock has traded between a 52-week low of $2.81 and a 52-week high of $43.65, demonstrating extreme volatility typical of small-cap biotechnology stocks. Without a specific current price provided in the source facts to calculate the exact percentage deviation, the wide trading range highlights the speculative nature of the asset relative to the broader market. The Beta is listed as N/A, meaning that the specific volatility metric relative to the broader market index is not disclosed in the available data, though the wide 52-week range implies high sensitivity to market sentiment.

Growth & Income

Revenue Growth (YoY) and Earnings Growth (YoY) are both listed as N/A, reflecting the early stage of the company where historical growth rates cannot be calculated due to the lack of established commercial revenue streams. Since the company does not currently distribute dividends, with a Dividend Yield of N/A and a Payout Ratio of 0.0%, the firm reinvests all available earnings and capital into advancing its clinical programs and research initiatives rather than providing income to shareholders. The absence of a dividend payout ratio confirms that the company's financial strategy prioritizes funding its clinical-stage development over returning capital to investors, which is standard practice for biotechnology firms seeking to secure regulatory approval for their STAT3-targeted therapies. Overall, the growth and income profile is defined by a reliance on external capital to fund R&D rather than internal cash generation or dividend income, with growth potential contingent entirely on the successful progression of its drug candidates through clinical trials.